Algorithmic Biologics is a technology company.
Algorithmic Biologics has raised $2.0M across 1 funding round.
Algorithmic Biologics has raised $2.0M in total across 1 funding round.
Algorithmic Biologics is a Bengaluru-based deep-tech startup founded in 2021, specializing in biotechnology and healthtech by developing computational platforms for biological data analysis and molecular testing workflows.[1][2][3] The company builds software that applies advanced algorithmic innovations to enhance molecular analysis, serving biotech researchers, labs, and healthtech firms facing inefficiencies in data-heavy biological processes; it has raised over $2M in funding and employs 11 people, indicating early growth momentum in a high-potential sector.[1][3]
Algorithmic Biologics was established in 2021 in Bengaluru, Karnataka, India, by Manoj Gopalkrishnan, whose background likely draws from computational biology expertise given the company's focus on algorithmic tools for biotech.[1] The idea emerged from the need for deep-tech solutions in molecular analysis, positioning it as a funded healthtech startup quick to secure investment amid rising demand for computational biology platforms.[2][3] Early traction includes raising $2M+ in funding, enabling a small but specialized team to build out its software platform.[3]
Algorithmic Biologics rides the wave of computational biology and AI-driven drug discovery, where exploding biological datasets demand faster analysis tools amid trends like precision medicine and personalized therapies.[1][2] Timing aligns with post-2021 biotech funding surges in India, fueled by global needs for efficient molecular workflows during health crises and genomic advancements.[3] Market forces like India's growing healthtech ecosystem and algorithmic scalability favor it, influencing the startup scene by bridging software with biotech R&D for quicker insights.[1]
Next steps likely involve platform scaling, deeper AI integrations for molecular predictions, and partnerships with pharma giants to accelerate testing pipelines. Trends like multimodal biological data fusion and regulatory pushes for computational validation will shape its path, potentially evolving it into a key enabler of next-gen biotech innovation. As a nimble Bengaluru player with solid early funding, it exemplifies how algorithmic biologics can transform data overload into discovery speed, echoing its origins in computational ingenuity.[1][2][3]
Algorithmic Biologics has raised $2.0M in total across 1 funding round.
Algorithmic Biologics's investors include Axilor Ventures, Bharat Innovation Fund, Som.
Algorithmic Biologics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $2.0M Seed | Axilor Ventures, Bharat Innovation Fund, Som |